View Older Stories View More Recent Stories

Mar 6, 2023 07:01AM Eisai, Biogen (BIIB) announced FDA accepts sBLA for LEQEMBI
Mar 5, 2023 06:30PM FDA Accepts Eisai’s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer’s Disea
Mar 5, 2023 06:30PM FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Feb 27, 2023 06:30PM Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration
Feb 27, 2023 06:30PM BIOLOGICS LICENSE APPLICATION FOR LECANEMAB DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Feb 23, 2023 10:53AM Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi - CNBC
Feb 6, 2023 06:51AM Biogen (BIIB), Sage Therapeutics (SAGE) announce FDA acceptance of NDA for zuranolone to treat MDD and PPD
Feb 6, 2023 06:30AM Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Feb 6, 2023 06:30AM Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Feb 6, 2023 06:30AM Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Jan 29, 2023 06:35PM Biogen (BIIB) Announces Lecanemab Receives Priority Review Status in Japan
Jan 29, 2023 06:30PM Lecanemab Receives Priority Review Status in Japan
Jan 29, 2023 06:30PM LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN
Jan 27, 2023 05:49AM Biogen (BIIB) Announces Marketing Authorization Application for Lecanemab Accepted in EU
Jan 26, 2023 06:30PM MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE ACCEPTED BY EUROPEAN MEDICINES AGENCY
Jan 26, 2023 06:30PM Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Jan 15, 2023 07:30PM EISAI FILES MARKETING AUTHORIZATION APPLICATION FOR ANTI-AMYLOID-BETA PROTOFIBRIL ANTIBODY LECANEMAB FOR EARLY ALZHEIMER'S DISEASE IN JAPAN
Jan 10, 2023 06:30PM EISAI SUBMITS MARKETING AUTHORIZATION APPLICATION FOR LECANEMAB AS TREATMENT FOR EARLY ALZHEIMER'S DISEASE IN EUROPE
Jan 6, 2023 11:30PM Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Jan 6, 2023 02:31PM Eisai, Biogen (BIIB) Confirm FDA Approval of LEQEMBI Under Accelerated Approval Pathway for Treatment of Alzheimer's Disease
Jan 6, 2023 02:30PM FDA Approves LEQEMBI™ (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease
Jan 5, 2023 07:30AM Biogen Names Priya Singhal as Executive Vice President, Head of Development
Jan 5, 2023 07:30AM Biogen Names Priya Singhal as Executive Vice President, Head of Development
Jan 4, 2023 07:30AM Biogen (BIIB), Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Jan 4, 2023 07:30AM Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Jan 4, 2023 07:30AM Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Dec 22, 2022 06:45PM EISAI INITIATES BLA SUBMISSION OF DATA FOR LECANEMAB IN CHINA
Dec 22, 2022 05:24AM PureTech Health (PRTC) Provides End of Year Update
Dec 22, 2022 02:00AM PureTech Provides End of Year Report on Key Progress
Dec 19, 2022 07:32AM Biogen (BIIB) Enters Deal with Genentech to Receive Royalties on Potential Commercialization of Bispecific Antibody as Part of Anti-CD20 Collaboration
Dec 19, 2022 07:30AM Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
Dec 19, 2022 07:30AM Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
Dec 9, 2022 07:30AM Biogen (BIIB) Announces FDA Accepts BLA for BIIB800, A Biosimilar Candidate Referencing ACTEMRA
Dec 9, 2022 07:30AM FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
Dec 9, 2022 07:30AM FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)
Dec 6, 2022 06:30AM Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
Dec 5, 2022 07:32AM Biogen (BIIB) Announces European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
Dec 5, 2022 07:30AM European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
Dec 5, 2022 07:30AM European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS
Nov 29, 2022 08:33PM Eisai, Biogen Phase 3 Results of Lecanemab in Early Alzheimer's Show Highly Statistically Significant Results
Nov 29, 2022 07:50PM ELEVEN EXPERTS FROM LEADING MEDICAL INSTITUTIONS AND EIGHT EXPERTS FROM EISAI* PUBLISH FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE IN THE NEW ENGLAND
Nov 29, 2022 07:50PM EISAI PRESENTS FULL RESULTS OF LECANEMAB PHASE 3 CONFIRMATORY CLARITY AD STUDY FOR EARLY ALZHEIMER'S DISEASE AT CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE
Nov 22, 2022 07:00AM Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
Nov 10, 2022 07:30AM Biogen Names Christopher Viehbacher President and Chief Executive Officer
Nov 10, 2022 07:30AM Biogen Names Christopher Viehbacher President and Chief Executive Officer
Oct 26, 2022 06:05AM Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
Oct 26, 2022 06:05AM Biogen Data at ECTRIMS 2022 Highlight Innovation in Digital Health Focused on Advancing Treatment and Personalized Care of People Living with MS
Oct 26, 2022 06:02AM Biogen (BIIB) Presents New Multiple Sclerosis Data
Oct 26, 2022 06:02AM New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
Oct 26, 2022 06:02AM New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized Disease Management for People Living with MS
View More Recent Stories View Older Stories